MabCampath (alemtuzumab) – Risk of Haemophagocytic Lymphohistiocytosis, Stroke (including ischaemic and haemorrhagic stroke), and Glomerulonephritis
https://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2020/73387a-eng.php